Home » Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

January 11, 2013

It’s a make or break year for GlaxoSmithKline. The UK’s largest pharmaceutical company is counting on a spate of drugs winning approval this year to reverse recent setbacks and revive growth.
Bloomberg

05Aug
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
10Aug
Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III
12Aug
On-Site Inspections: They’re Back — But When, Where and How
16Aug
Using AI for CAPA and Root Cause Investigation
28Sep
4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit
12Oct
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III

On-Site Inspections: They’re Back — But When, Where and How

Using AI for CAPA and Root Cause Investigation

4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit

Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Creditors Show Support for Purdue Pharma’s Bankruptcy Plan

Prescient Imaging Gains 510(k) Clearance for Portable PET Scanner

First Interchangeable Biosimilar Insulin Secures FDA Approval

Lazarus Gets FDA 510(k) Clearance for Pre-Sure Surgical Technology

The Revised ICH E8: A Guide to New Clinical Trial Requirements